Blinatumomab in pediatric patients with relapsed/refractory B?cell precursor acute lymphoblastic leukemia

Objective Pediatric patients with relapsed or refractory acute lymphoblastic leukemia have a poor prognosis. We here assess the response rates, adverse events, and long-term follow-up of pediatric relapsed/refractory receiving blinatumomab. Methods Retrospective analysis single-center experience blinatumomab in 38 over period 10 years. Results The median age at onset therapy was years (1-21 years). Seventy-one percent had undergone least one hematopoietic stem cell transplantation (HSCT) prior to treatment observed 13/38 (34%). predominant side effect febrile reactions, nearly half developed cytokine release syndrome. Eight events neurotoxicity were registered 78 cycles (15%). To date, nine (24%) are alive complete molecular remission. All survivors underwent haploidentical HSCT after Conclusions Despite heavy pretreatment most our patients, severe rare rates encouraging. Blinatumomab is valuable bridging salvage for second even third HSCT.